Posted by Michael Wonder on 12 Feb 2020
Decision for funding in the blood, alimentary and immunosuppressant therapy areas
12 February 2020 - PHARMAC is pleased to announce a decision to approve proposals relating to medicines in the blood, alimentary and immunosuppressant therapy areas.
In summary, this will result in the following changes from 1 March 2020:
- Tcagrelor (Brilinta) access will be widened to include prevention of thrombosis in patients who have had a neurological stent
- Budesonide capsules (Entocort CIR) access will be widened to include the treatment of patients with non-cirrhotic autoimmune hepatitis
- Etanercept (Enbrel) access will be widened to include treatment of patients with undifferentiated spondyloarthritis
- Ruxolitinib (Jakavi) access will be widened to include patients with lower risk (intermediate-1) myelofibrosis
